Quantcast

Latest gene delivery Stories

2014-07-11 08:25:10

DUBLIN, July 11, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "International Transfection Technology Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast to 2019" report to their offering. http://photos.prnewswire.com/prnh/20130307/600769 Transfection is a technique used to introduce nucleic acids (either DNA or RNA) into cells. This technology helps the cells to regulate gene therapy, mutation of cancer cells and protein metabolism by...

2014-07-07 12:28:59

Engineered Cells Known As CTL019 Are the First Therapy of Their Kind to Obtain Designation PHILADELPHIA, July 7, 2014 /PRNewswire/ -- A University of Pennsylvania-developed personalized immunotherapy has been awarded the U.S. Food and Drug Administration's Breakthrough Therapy designation for the treatment of relapsed and refractory adult and pediatric acute lymphoblastic leukemia (ALL). The investigational therapy, known as CTL019, is the first personalized cellular therapy for the...

2014-06-28 12:53:00

Texas A&M AgriLife Communications Scientists with Texas A&M AgriLife Research have found a "Trojan horse" way to deliver proteins into live human cells without damaging them. The finding, published in this month's Nature Methods, is expected to be easily adopted for use in medical research to find cures and treatments for a wide range of diseases, according to the team's lead scientist, Dr. Jean-Philippe Pellois, an associate professor of biochemistry at Texas A&M...

2014-06-19 08:28:26

RICHMOND, Calif., June 19, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc. (NASDAQ: SGMO) announced the appointment of H. Stewart Parker to the Company's Board of Directors. Ms. Parker, who founded and served as President and CEO of Targeted Genetics Corporation, brings more than 30 years of experience in the biotechnology industry, including 16 years of specific experience in cell and gene therapy. http://photos.prnewswire.com/prnvar/20130102/SF35903LOGO "We are very pleased to...

2014-06-16 08:29:08

Company will draw on leaders' expertise in rare diseases, R&D and commercialization as it moves to complete development of its lead program in inherited blindness PHILADELPHIA, June 16, 2014 /PRNewswire/ -- Spark Therapeutics, a late-stage gene therapy company developing treatments for a wide range of rare, debilitating diseases, announced today the appointments of Lars Ekman, former president of research and development at Elan, and Vin Milano, former president and CEO of...

2014-06-10 13:27:17

Duke University Ubiquitous protein controls copying of resistant DNA Staph infections that become resistant to multiple antibiotics don't happen because the bacteria themselves adapt to the drugs, but because of a kind of genetic parasite they carry called a plasmid that helps its host survive the antibiotics. Plasmids are rings of bare DNA containing a handful of genes that are essentially freeloaders, borrowing most of what they need to live from their bacterial host. The plasmids...

2014-06-05 23:01:58

Barbara and Edward Netter awarded prestigious distinction by the American Society of Gene and Cell Therapy. Washington, DC (PRWEB) June 05, 2014 Barbara Netter and her late husband Edward Netter – Greenwich residents and founders of Alliance for Cancer Gene Therapy (ACGT) – were awarded the prestigious Distinguished Service Award by the American Society of Gene and Cell Therapy (ASGCT) on Thursday, May 22, 2014. The award – presented in Washington, DC before an audience of over...

2014-06-02 16:25:27

PHILADELPHIA, June 2, 2014 /PRNewswire/ -- Spark Therapeutics, Inc., a late-stage gene therapy company developing treatments for a wide range of rare, debilitating diseases, announced today that company leadership will present at three healthcare investor meetings in June. -- 2014 Jefferies Global Healthcare Conference, New York City, June 5 Jeffrey D. Marrazzo, co-founder and CEO of Spark, will present on Spark's leadership in the advancement of potentially curative,...

2014-05-28 16:26:41

Groundbreaking Nature Publication Describes Successful ZFN Driven Genome Editing in Long-Term Repopulating Stem Cells Necessary for Clinical Translation RICHMOND, Calif., May 28, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the publication in Nature of data demonstrating efficient zinc finger nuclease (ZFN)-mediated, targeted gene insertion that resulted in correction of the genetic defect in stem cells from an individual with X-linked severe combined...

2014-05-27 16:25:11

Gene therapy leader to advance its deep pipeline of rare disease programs including its lead Phase 3 product candidate for RPE65-related blindness PHILADELPHIA, May 27, 2014 /PRNewswire/ -- Spark Therapeutics, a late-stage company developing gene-based medicines for a wide range of rare, debilitating diseases, today announced the successful completion of a $72.8 million Series B financing led by Sofinnova Ventures. Joining Sofinnova as new investors in the company are Brookside...


Word of the Day
mundungus
  • A stinking tobacco.
  • Offal; waste animal product; organic matter unfit for consumption.
This word comes from the Spanish 'mondongo,' tripe, entrails.